Retroviral Vector Delivery of Reprogramming Factors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for nuclear reprogramming of somatic cells to derive induced pluripotent stem cells face ethical concerns and rejection issues due to the use of embryos or embryonic stem cells, and lack reliable and safe techniques for generating pluripotent stem cells.
Innovation Solution
The use of nuclear reprogramming factors such as gene products from the Oct, Klf, Myc, and Sox families, along with cytokines like bFGF and SCF, to reprogram somatic cells into induced pluripotent stem cells without requiring eggs, embryos, or embryonic stem cells, thereby establishing pluripotent stem cells with similar growth and differentiation abilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nuclear transfer into oocytes or fusion with ES cells is used for reprogramming, then pluripotent stem cells can be generated, but ethical problems and rejection issues occur
Solution Approach 1:
The patent extracts and identifies the specific nuclear reprogramming factors (Oct3/4, Sox2, Klf4, c-Myc) responsible for inducing pluripotency, separating them from the problematic methods of nuclear transfer and ES cell fusion. By isolating these molecular factors, the invention enables reprogramming without requiring oocytes, embryos, or ES cells, thus eliminating ethical concerns and rejection issues while maintaining reprogramming effectiveness
Solution Approach 2:
The patent introduces retroviral vectors as intermediary carriers to deliver the nuclear reprogramming factors into somatic cells. These viral vectors serve as mediators that efficiently transfer the reprogramming genes without requiring direct contact with embryos or ES cells, providing a safe and ethical pathway to generate iPS cells
2Ease of operation
If cell extracts are used to treat differentiated cells, then reprogramming may occur, but the technique is unreliable and unsafe due to mixed unknown factors
Solution Approach 1:
The patent segments the complex cell extract into individual, identified nuclear reprogramming factors (Oct3/4, Sox2, Klf4, c-Myc). By dividing the unknown mixture into specific, characterized components, the invention enables precise control over the reprogramming process, improving both reliability and safety while maintaining operational simplicity through defined molecular targets
Solution Approach 2:
The patent replaces the crude mechanical approach of using whole cell extracts with a molecular-level substitution using specifically identified transcription factors delivered via retroviral vectors. This substitution transforms an unreliable, unknown mixture into a defined, controllable set of molecular agents with known functions and safety profiles
Data Source
AI summary
The present invention relates to a nuclear reprogramming factor having an action of reprogramming a differentiated somatic cell to derive an induced pluripotent stem (iPS) cell. The present invention also relates to the aforementioned iPS cells, methods of generating and maintaining iPS cells, and methods of using iPS cells, including screening and testing methods as well as methods of stem cell therapy. The present invention also relates to somatic cells derived by inducing differentiation of the aforementioned iPS cells.